Allergan Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (59)

Latest Posts

About This Stock More About This Stock
Allergan Q4 Earnings Beat On Increase In Botox Sales
Article By: Zacks Investment Research
Tuesday, February 6, 2018 1:00 PM EST
Allergan plc’s fourth-quarter 2017 earnings came in at $4.86 per share.
In this article: AGN Also: SHPG, MYL, SGYP
Read
Patent Losses Could Sink Allergan
Article By: Shock Exchange
Monday, February 5, 2018 9:04 AM EST
Allergan reports Q4 earnings on Tuesday. The company faces patent losses for Restasis, Combigan and Estrace. They represent a combined 15% of total revenue.
In this article: AGN Also: TEVA, MYL, NVS
Read
Allergan Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly
Monday, January 29, 2018 6:49 AM EST
Barclays analyst Douglas Tsao upgraded Allergan to Overweight and raised his price target for the shares to $230 from $220.
In this article: AGN
Read
Allergan Fires 1,000 In Hopes Of Halting Stock Slide
Article By: Tyler Durden
Wednesday, January 3, 2018 1:01 PM EST
Allergan said it plans to cut more than 1,000 jobs and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.
In this article: AGN
Read
Valeant, Ackman Settle Insider Trading Lawsuit For $290 Million
Article By: Shock Exchange
Wednesday, January 3, 2018 7:25 AM EST
Valeant and Pershing Square settled their AGN insider trading case for $290MM. The settlement saved substantial time and resources. I believe there is a potential for future AGN shareholders to sue, creating a need for more settlements.
In this article: VRX, PSHZF, AGN
Read

PARTNER HEADLINES

Latest Tweets for $AGN

No tweets yet!

$AGN

Patent Losses Could Sink Allergan
Dean Gilmore 2/5/2018 2:37:30 PM

Look at where $AGN was a year ago. It has lost a chunk of it's value already. This news won't help.

Patent Losses Could Sink Allergan
Alpha Stockman 2/5/2018 2:26:42 PM

These hits all hurt #Allergan's bottom line but aren't it's cash cows like #Botox which still does very well for the company and will only only generate even more revenue over time. $AGN

Patent Losses Could Sink Allergan
Ayelet Wolf 2/5/2018 2:22:51 PM

This news sounds catastrophic to me. Why isn't #Allergan tanking? $AGN

Valeant Edges Up 15% After Announcing That It Will Acquire Salix
Terry Caruso 2/24/2015 8:20:44 PM

You said the company tried to acquire Allergan but the deal fell through because Valeant didn't like it's large R&D program. If true, why did it try to acquire $AGN in the first place?

1 to 4 of 4 comments